Suppliers / Cambrex Profarmaco Milano

Cambrex Profarmaco Milano

Italy 2 duplicate records merged Updated 9 July 2026

Cambrex Profarmaco Milano is an API manufacturer based in Italy. It holds 94 active US drug master files and 18 valid CEPs. Its most recent recorded inspection, by US FDA, closed on 11 November 2022 as NAI.

94
active US DMFs
18
valid CEPs
2
registered plants 1 with an FDA FEI number
8
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
7 of 7 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 11 November 2022 NAI US FDA
  • 1 October 2021 VAI US FDA
  • 7 May 2019 NAI US FDA
  • 19 May 2017 VAI US FDA
  • 6 November 2015 VAI US FDA
  • 25 March 2011 NAI US FDA
  • 31 March 2009 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Italy, Italy 3003723076
Paullo, Italy Not on file

What they file, and where

Molecule Regulators Docs
Epinephrine EDQM, SFDA (Saudi Arabia), US FDA 8
Midazolam EDQM, SFDA (Saudi Arabia), US FDA 8
Norepinephrine EDQM, SFDA (Saudi Arabia), US FDA 5
Chlordiazepoxide US FDA 4
Clozapine EDQM, SFDA (Saudi Arabia), US FDA 4
Cysteamine US FDA 4
Lacosamide EDQM, SFDA (Saudi Arabia), US FDA 4
Alprazolam EDQM, US FDA 3
Amiodarone EDQM, US FDA 3
Glyburide SFDA (Saudi Arabia), US FDA 3
Show all 30 molecules on file
Hydrochlorothiazide EDQM, US FDA 3
Lorazepam EDQM, US FDA 3
Rifaximin EDQM, US FDA 3
Sodium Picosulfate EDQM, US FDA 3
Sotalol SFDA (Saudi Arabia), US FDA 3
Zolpidem EDQM, US FDA 3
Albuterol US FDA 2
Bisacodyl US FDA 2
Chlorothiazide US FDA 2
Clobazam US FDA 2
Clonazepam US FDA 2
Clorazepic Acid US FDA 2
Cromoglicic Acid US FDA 2
Dapagliflozin US FDA 2
Diazepam US FDA 2
Diltiazem US FDA 2
Eltrombopag US FDA 2
Estazolam US FDA 2
Flurazepam US FDA 2
Glipizide US FDA 2

Also appears on these molecule pages

Show 3 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 8 None

Comparing suppliers?

Choose your molecules and target markets. Cambrex Profarmaco Milano comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 4 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 11 November 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability